SAN DIEGO, March 8 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN),
developer of advanced diagnostic products, announced today its subsidiary SynX
signed five new European distributors for its point-of-care products. The
additional distribution agreements significantly increase SynX's coverage to
28 European nations. All of SynX's European distributors were selected based
on prior experience in the point-of-care medical device and equipment sector,
as well as knowledge with cardiac and central nervous system diseases. Each
partner will be responsible for the distribution and marketing of SynX's
point-of-care tests and research oriented products for congestive heart
failure (CHF) and myocardial infarction. Expected to be commercially
available in 2005, the CHF diagnostic product will measure NT-proBNP
(N-terminal pro-hormone brain natriuretic peptide), a sensitive and specific
biomarker for the diagnosis of congestive heart failure.
"These new distribution partners complement our existing distributor
networks and provide us with significant relationships with point-of-care
diagnostic decision makers in the hospital and research market segments," said
Howard C. Birndorf, Nanogen's chairman of the board and chief executive
officer. "Development of our congestive heart failure test is progressing and
expansion of our distribution network is a key objective that will be
important to the success of the product."
The newly expanded network provides SynX with exposure to a potential
customer base of over 7,500 hospitals, 4,000 clinical laboratories and almost
11,000 cardiac specialists as measured by the European Diagnostic
Manufacturers Association, excluding the newly emerging EU nations.
About Nanogen, Inc.
Nanogen's advanced diagnostics provide physicians and patients worldwide
with sophisticated information to predict, diagnose and treat disease.
Research and clinical reference labs use the highly accurate and reliable
NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray
and broad suite of analyte specific reagents to develop tests to detect
infectious diseases, drug toxicity and mutations associated with cancer,
cardiovascular and genetic diseases. The next generation instrument system,
the NanoChip(R) 400, is expected to be available in 2005. Nanogen's subsidiary
SynX offers a line of point-of-care diagnostic tests and is building expertise
in cardiac related health conditions. Nanogen's ten years of pioneering
research involving nanotechnology may also have future applications in medical
diagnostics, biowarfare and other industries. For additional information
please visit Nanogen's website at www.nanogen.com.
This press release contains forward-looking statements that are subject to
risks and uncertainties that could cause actual results to differ materially
from those set forth in the forward-looking statements, including whether
patents owned or licensed by Nanogen will be developed into products, whether
the patents owned by Nanogen offer any protection against competitors with
competing technologies, whether products under development can be successfully
developed and commercialized, whether results reported by our customers or
partners can be identically replicated, and other risks and uncertainties
discussed under the caption "Factors That May Affect Results" and elsewhere in
Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date hereof. Nanogen disclaims any intent or obligation to update these
SOURCE Nanogen, Inc.